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ACELLULARIZED BIOMATERIAL FROM 
EMBRYONIC STEM CELLS 
RELATED APPLICATION 
This application is a filing under 35 U.S.C. §371 of PCT/ 
US2006/043711 filed with the U.S. Receiving Office of the 
Patent Cooperation Treaty on Nov. 8, 2006, and claims benefit 
of and priority to U.S. Provisional Patent Application No. 
60/734,584 filed on Nov. 8, 2005, and where permissible is 10 
incorporated by reference herein in its entirety. 
GOVERNMENT SUPPORT 
2 
It is also an object of the present invention to provide 
methods and compositions that promote wound healing, pro-
mote tissue regeneration, or reduce scarring. 
SUMMARY OF THE INVENTION 
Aspects of the disclosure provide acellularized biomaterial 
derived from pluripotent cells, for example differentiating 
stem cells. Certain aspects provide acellularized biomaterial 
derived from differentiating embryonic stem cells (ESC). 
Acellularized tissues have been examined before in various 
wound healing models, but the tissue source for the acellular 
biomaterial was never derived from an embryonic source 
actively undergoing differentiation for example, morphogen-
esis. Moreover, existing stem cell therapies are based on the 
Aspects of the work disclosed herein were supported, in 
part, by Grant No. EEC-9731643 awarded by the National 
Science Foundation. Accordingly, the U.S. govermnent has 
certain rights in the claimed subject matter. 
15 administration of stem cells which differentiate in vivo to 
regenerate damaged or missing tissue. Aspects of the disclo-
sure are based on the principle that biomolecules synthesized 
by stem cells may be as important, if not more so, than 
functional differentiation of the cells. Thus, the application of 
FIELD OF THE INVENTION 
Aspects of the invention are generally directed to acellu-
larized biomaterial compositions, in particular acellularized 
biomaterial compositions derived from embryonic stem cells. 
20 stem cells themselves is not as important as the application of 
biomolecules produced by stem cells. This represents a fun-
damental paradigm shift in stem cell regenerative therapies. It 
is believed that the disclosed acellularized biomaterial pro-
vides a complex of molecules with potent regenerative abili-
BACKGROUND OF THE INVENTION 
25 ties in adult wound healing environments. The acellularized 
biomaterial also provides a system to deliver embryonic 
molecular morphogenic cues directly to adult tissues. 
Other aspects provide methods of treating a degenerative 
disease by administering the acellularized biomaterial 
30 derived from differentiating embryonic stem cells in an 
amount effective to promote healing or tissue regeneration. 
The acellularized biomaterial can be administered in combi-
nation or alternation with pluripotent cells or other cell types. 
A number of different stem cells, including embryonic, 
bone marrow and cardiac progenitors, are currently being 
examined as potential therapies to repair injured tissues, for 
example myocardium. These approaches typically focus on 
regenerating cellularity and restoring tissue function. Thus 
far, independent of the particular cell type, stem cell therapies 
have consistently demonstrated enhancements in tissue func- 35 
tion in experimental models and clinical trials. However, the 
precise mechanisms responsible for global functional 
improvements have yet to be fully elucidated since improve-
ments can be detected even in the absence of any substantial 
amount of regenerated tissue. This suggests that even if stem 40 
cells capable of differentiating into specific cell types are 
delivered to a damaged tissue, intrinsic signals capable of 
directing tissue specific differentiation may be absent or defi-
cient within the microenvironment of the damaged tissue. 45 
To date, biomaterials utilized in tissue restoration therapies 
have largely served a structural role as either a delivery 
vehicle for tissue and tissue engineering or as a patch for 
tissue defects. Despite the clear therapeutic potential of stem 
cells, several drawbacks, including the potential immunoge- 50 
nicity and tumorigenicity of the cells in vivo still exist. 
The extracellular matrix (ECM), largely composed of 
adhesive proteins, cytokines and polysaccharides, constitutes 
the biochemical and mechanical nature of the microenviron-
A particular aspect provides a method for treating a cardiac 
disorder by administering acellularized biomaterial derived 
from differentiating embryonic stem cells in an amount effec-
tive to promote healing or tissue regeneration. 
Another aspect provides a method to reduce or inhibit scar 
formation in host by administering acellularized biomaterial 
derived from differentiating pluripotent cells to the wound or 
damaged tissue. 
Still another aspect provides a medical device, for example 
a stent at least partially coated with acellularized biomaterial 
derived from differentiating pluripotent cells. 
BRIEF DESCRIPTION OF THE DRAWINGS 
FIG. 1 shows bar graphs of normalized cell viability of 
embryoid bodies versus Triton X-100 concentration (A) or 
DNase concentration (B). 
FIG. 2 shows bar graphs of protein concentration of embry-
oid bodies versus Triton X-100 concentration (A); Triton X 
duration (B); DNase concentration (C); and DNase duration 
(D). 
FIG. 3 shows bar graphs of normalized cell viability versus 
embryoid bodies treated with Triton X 100, DNase, or both 
(A); protein concentration of embryoid bodies treated with 
Triton X 100, DNase, or both (B); and cell density of embry-
oid bodies treated with Triton X 100, DNase, or both (C). 
FIG. 4 shows bar graphs of normalized percent viability 
versus duration of treatment of embryoid bodies with DNase 
combined with Triton X 100 (A); DNA content versus time 
(B); and protein content versus time (C). 
ment that regulates cell fate and function within tissues. Curi- 55 
ously, very little is known about the complex assembly of the 
ECM present during early cell and tissue development though 
these molecules are thought to provide critical cues that 
instruct cell behavior. Pluripotent ES cells provide an in vitro 
model of development and are currently being examined in a 60 
number of experimental models as a potential cell therapy to 
regenerate diseased or injured tissues. However, thus far, no 
studies have examined the role of the extracellular matrix 
contributed by ES cells to tissue repair processes. FIG. 5 shows bar graphs of protein concentration versus 
65 day of differentiation (A); mass versus day of differentiation 
(B); and DNA content versus day of differentiation (C) of 
embryoid bodies. 
It is an object of the present invention to provide acellular-
ized biomaterial derived from pluripotent cells, for example 
embryonic stem cells. 
US 9,211,307 B2 
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FIG. 6 shows a bar graph of normalized cell viability versus 
day of differentiation. 
FIG. 7 shows a bar graph of embryoid body formation 
using rotary or static culture procedures. 
FIG. 8 shows a scatter plot of beating embryoid bodies 
produced using static or rotary culture procedures. 
FIG. 9 shows bar graphs indicating fold increase in Nanog 
(A), Brachyury T (B), or MLC-2v (C) expression of embryoid 
bodies produced using static or rotary culture procedures. 
DETAILED DESCRIPTION OF THE INVENTION 
I. Definitions 
10 
The term "acellularized biomaterial" refers to material pro-
duced from a living organism that no longer contains living 15 
cells. 
The term "adult tissue" refers to tissue from an organism 
that has completed gestation. In certain embodiments, adult 
tissue does not include fetal or embryonic tissue. 
The term "cardiac differentiation" refers to totipotent or 20 
pluripotent cells undergoing developmental events leading to 
the acquisition of one or more characteristics of a cardiac cells 
and/or tissue. 
The term "control" refers to an experiment performed 
without the active ingredient, for example without acellular- 25 
ized biomaterial. Controls are known in the art. 
The term "disease" refers to a disordered or incorrectly 
functioning organ, tissue, structure, or system of the body of 
an organism resulting from the effect of genetic or develop-
mental errors, infection, poisons, nutritional deficiency or 30 
imbalance, toxicity, or unfavorable environmental factors. 
The term "embryonic stem cell" refers to cells derived 
from the inner cell mass of a developing blastocyst, for 
example a mouse or human blastocyst, and are known to be 
"pluripotent", meaning that they can differentiate into any 35 
somatic cell type. 
4 
and parts of the organism's body. The acellularized biomate-
rial can be functionally capable of inducing or facilitating 
wound healing including regenerative tissue repair in vitro or 
in vivo. The acellularized material can also contain extracel-
lular material, optionally in combination with paracrine fac-
tors produced by the embryonic stem cells. Typically the 
acellularized material contains paracrine factors produced by 
the pluirpotent cells, such as embryonic stem cells, as the cells 
differentiate in vitro, for example into a specific tissue type. 
Embryonic stem cells can differentiate into any cell type, 
for example, epidermal, mesodermal, or endodermal cell 
types or tissues. Thus, acellularized material can be produce 
that is specific for epidermal, mesodermal, or endodermal 
derived tissues or wounds in specific tissues. 
Exemplary specific tissues include, but are not limited to 
cardiac, bone, skin, skeletal muscle, smooth muscle, arterial 
tissue, ocular tissue, neural tissue, skin tissue, liver tissue, 
pancreatic tissue, insulin-producing tissue, or combinations 
thereof. 
The paracrine factors can be linked, conjugated, or 
covalently bound to the extracellular material. In certain 
embodiments, the paracrine factors can diffuse out of the 
acellularized biomaterial and into the wound or damaged 
tissue. The diffusion of the paracrine factors can produce a 
gradient of one or more paracrine factors across a section of 
the wound or damaged tissue. Additionally, the acellularized 
biomaterial can function as a controlled release device for the 
controlled, sustained delivery of stem cell paracrine factors. 
In other embodiments, the acellularized material physi-
cally interacts with the wound or damaged tissue to promote 
healing. The healing can result from the physical interaction 
alone or in combination with paracrine factors released from 
the acellularized biomaterial. 
Another embodiment provides acellularized biomaterial 
derived from embryonic stem cells having inherent regenera-
tive properties for tissue restoration and wound repair can be 
used independently or in conjunction with cell therapies. 
It is believed that the disclosed acellularized biomaterial 
advantageously promotes, facilitates, or induces wound heal-
The term "epidermal differentiation" refers to the differen-
tiation of a pluripotent or totipotent cell into an epidermal cell 
type such that the totipotent or pluripotent cell acquires one or 
more characteristics of an epidermal cell type. 
The term "heterologous nucleic acid" refers to a nucleic 
acid derived from another organism. 
40 ing, including but not limited to regenerative tissue repair, by 
altering the microenvironment of the wound or damaged tis-
sue to more closely resemble the microenvironment of devel-
oping tissue, for example embryonic tissue. The acellularized The term "myogenic differentiation" refers to the differen-
tiation of a pluripotent or totipotent cell into a mesodermal 
cell type such that the totipotent or pluripotent cell acquires 45 
one or more characteristics of a mesodermal cell type 
The term "neural differentiation" refers to the differentia-
tion of a pluripotent or totipotent cell into a neural cell type 
such that the totipotent or pluripotent cell acquires one or 
more characteristics of a neural cell type. 
The term "paracrine factor" refers to a substance secreted 
by an embryonic stem cell that acts on adjacent cells. Repre-
sentative paracrine factors include, but are not limited to 
growth factors, mitogens, cytokines, developmental factors 
or cues, or combinations thereof. 
The term "regenerative tissue repair" refers to repair of 
damaged tissue by inducing cells of the damaged tissue to 
replace the damaged cells or tissue. 
The term "wound" refers to damage to a tissue or organ and 
can be external or internal. 
II. Compositions 
One embodiment provides acellularized biomaterial 
derived from pluripotent cells such as embryonic stem cells 
undergoing differentiation, for example in vitro. Differentia-
tion includes morphogenesis. Morphogenesis refers to differ-
entiation of cells and tissues in the early embryo which results 
in establishing the form and structure of the various organs 
biomaterial alters the microenvironment of the wound by 
physically interacting with cells of the wound or tissue and 
optionally by delivering stem cell paracrine factors to cells in 
and around the wound in amounts, concentrations, and dura-
tions effective to cause the cells in the wound or damaged 
tissue to participate in the healing process. Thus, unlike exist-
50 ing stem cell therapies that attempt to add stem cells and have 
the stem cells reproduce to form tissue, it is believed that the 
disclosed acellularized material causes existing cells in the 
wound or damage tissue to undergo biological changes that 
55 
promote healing. 
The components of the acellularized biomaterial are 
described more fully below. 
A. Embryonic Stem Cell Biomaterial 
1. Embryonic Stem Cells 
The disclosed acellularized biomaterial is produced by 
60 pluripotent cells or stem cells, preferably embryonic stem 
cells. The embryonic stem cells can be mammalian. In other 
embodiments, the stem cells can be non-human stem cells or 
chimeric stem cells produced, for example, from a human and 
a non-human manimal. It will be appreciated that any stem 
65 cell producing one or more extracellular matrix components 
and paracrine factors can be utilized to produce the disclosed 
acellularized biomaterial. Embryonic stem (ES) cells are 
US 9,211,307 B2 
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derived from the inner cell mass of a developing blastocyst, 
for example mouse, human, or non-human blastocyst, and are 
known to be "pluripotent", meaning that they can differenti-
ate into any somatic cell type. Their ability to differentiate 
into cell types, such as cardiomyocytes, neurons and hepato-
cytes, in vitro and in vivo, suggests they could be applicable 
to a number of degenerative cellular disorders in which 
endogenous mechanisms of cell replacement fail to 
adequately regenerate tissues. ES cells are typically cultured 
in Petri dishes on a layer of feeder cells or on a matrix-coated 10 
substrate and supplemented with soluble factors to stimulate 
cell growth in an "undifferentiated" state. In order to initiate 
differentiation, the adherent ES cells are displaced from the 
surface and placed in suspension culture, whereupon they 
form aggregates of cells referred to as embryoid bodies 15 
(EBs ). Individual EBs recapitulate most of the molecular 
signaling and cell differentiation events of embryonic post-
implantation tissues, including differentiation of the cells into 
the three germ lineages ( ectoderm, endoderm and mesoderm) 
from which all other progenitor cells and subsequent somatic 20 
cells are formed. Molecular environments within EBs regu-
late the course of cellular differentiation that ensues. Thus, 
another embodiment provides acellularized biomaterial 
derived from mammalian embryoid bodies, including but not 
limited to non-human embryoid bodies, differentiating in 25 
vitro. 
2. Extracellular Matrix Material 
The disclosed acellularized biomaterials include one or 
more extracellular matrix (ECM) components, for example, 
structural components, functional components, or a combi- 30 
nation thereof. The ECM is widely known to have both struc-
tural and functional components responsible for maintaining 
normal tissue homeostasis and the ECM undergoes dynamic 
changes in response to perturbations, such as cell or tissue 
injury, or the onset of degenerative disease. Much less is 35 
known about the roles of the ECM in morphogenic events, 
such as during developmental biology and tissue regenera-
tion, perhaps due to lack of a suitable mammalian model, 
particularly for regeneration. 
6 
(BMP), as well as their antagonists, such as noggin and chor-
din for BMPs, can also be found in the ECM. The nucleic acid 
and amino acid sequences for the genes and proteins dis-
cussed above are known in the art and can be found, for 
example in GENBANK. 
In addition to the homeostatic role of the ECM in tissue 
maintenance, the dynamic nature of the ECM in response to 
tissue injury or disease can significantly influence the course 
and outcome of wound healing and regeneration. Specifi-
cally, fibronectin has been found to be an important molecule 
for normal tissue morphogenesis and regeneration. Another 
component found to be important for morphogenesis is the 
basement membrane protein, laminin. Hyaluronic acid (HA) 
is yet another molecule of potential regenerative interest and 
has a role in binding growth factors and cytokines and pro-
moting water retention. It has been considered for induction 
of regenerative events in the past due to its high concentration 
in newborn and fetal tissue as well as its involvement in cell 
migration and wound repair processes. 
Additionally, several WNT proteins have been identified to 
play a critical role in limb regeneration in lower organisms 
and bone growth in mammals. As their name implies, BMP 
proteins are essential components of the normal bone forma-
tion and inhibition of the BMP pathway has been found to 
have a significant effect on regeneration events. The combi-
nation and concentration ofECM proteins and paracrine fac-
tors can be adjusted depending on the type of tissue needing 
repair. 
B. Cellular Therapy 
The disclosed acellularized biomaterial can optionally be 
used in combination or alternation with cellular therapies. 
Thus, the biomaterial can be seeded with one or more cells or 
types of cells to promote or facilitate healing. The seeding can 
occur before or afterthe acellularized biomaterial is delivered 
to the wound or damaged tissue. The types of cells used to 
seed the biomaterial can be selected based on the type of 
wound or damaged tissue to be treated. Generally, pluripotent 
cells can be used to seed the biomaterial so that the seeded 
cells and the biomaterial interact synergistically to promote 
healing. In one embodiment, the pluripotent cells thereof 
respond in vivo to the acellularized biomaterial and the para-
crine factors associated with the acellularized biomaterial and 
differentiate into a predetermined cell type or tissue. It will be 
appreciated that other cell types, including but not limited to 
stem cells, somatic cells, or a combination thereof can be used 
in combination with the acellularized material. 
For example, acellularized biomaterial specific for cardiac 
Two primary components of the ECM are proteins and 40 
polysaccharides (i.e., glycosaminoglycans (GAGs)). ECM 
proteins, such as collagen I and IV, fibronectin, and laminin 
play structural and functional roles in the maintenance of 
tissues. Collagen I is typically the most abundant protein in 
the ECM of adult tissues, however, over 20 different types of 45 
collagen have been discovered, each with their own function. 
Collagen IV, for example, is present in the basement mem-
brane of vascular structures and serves as a ligand for endot-
helial cells. Fibronectin is both a structural and functional 
protein, as it is a ligand for several different cell types. Lami-
nin is yet another protein prevalent in the basement mem-
brane and has been found to play a role in vascular structure 
maintenance. Growth factors, such as fibroblast growth factor 
(FGF), hepatocyte growth factor (HGF), platelet-derived 
growth factor (PDGF), vascular endothelial cell growth factor 55 
(VEGF), and insulin-like growth factor (IGF), can bind 
directly to ECM proteins or via proteoglycans or GAGs and 
50 material can be obtained from embryonic stem cells by cul-
turing the embryonic stem cells under conditions and a dura-
tion that induce the embryonic stem cells to differentiate into 
cardiac or cardiac-like material. The biomaterial can be acel-
be stably retained in a bound state within the ECM. Most of 
these growth factors also come in several distinct isoforms 
that can affect cells in different manners depending on asso- 60 
ciated biochemical elements within the context of the matrix. 
lularized, and optionally stored. The biomaterial can then be 
combined with cells prior or subsequent to delivering the 
biomaterial to the wound or damaged tissue, for example 
cardiac tissue. 
1. Pluripotent or Totipotent Cells 
Representative cells that can be used in combination with 
the acellularized biomaterial derived from embryonic stem 
cells include, but are not limited to, mammalian, human, or 
non-human embryonic or adult stem cells; pluripotent or 
totipotent cells obtained from placenta, cord blood, adipose 
tissue, neural tissue, muscle tissue, cardiac tissue, epidermal 
A number of GAGs, including chondroitin sulfate, heparin 
sulfate, and hyaluronic acid, and proteoglycans, such as per-
lecan, versican, and decorin are also often present in the 
ECM. GAGs and proteoglycans have multiple functions in 
the ECM, including binding growth factors. Potent morpho-
genic molecules like WNTs and bone morphogenic proteins 
65 tissue, or bone marrow; autologous cells, heterologous cells, 
or somatic cells optionally corresponding to the tissue to be 
treated. 
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2. Recombinant Cells 
The cells used in combination with the disclosed acellular-
ized biomaterial can be recombinant cells that express one or 
more heterologous nucleic acids. The heterologous nucleic 
acid can express a protein involved in wound healing or tissue 
regeneration, for example an extracellular matrix protein, 
matrix metalloprotease or GAG synthase, or a fusion protein 
thereof. Alternatively, the cell can be genetically engineered 
8 
amount of from 50 mg to 500 mg, even more preferably in an 
amount of from about 30 mg to about 100 mg. 
Representative excipients include, but are not limited to, 
water, acetone, ethanol, ethylene glycol, propylene glycol, 
butane-1,3-diol, isopropyl myristate, isopropyl palmitate, 
mineral oil, gelatin, casein, lecithin, gum acacia, cholesterol, 
tragacanth, stearic acid, benzalkonium chloride, calcium 
stearate, glyceryl monostearate, cetostearyl alcohol, 
cetomacrogol emulsifying wax, sorbitan esters, polyoxyeth-to secrete embryonic stem cell paracrine factors including, 
but not limited to growth factors such as fibroblast growth 
factor, hepatocyte growth factor, platelet-derived growth fac-
tor, vascular endothelial cell growth factor, and insulin-like 
growth factor, bone morphogenic proteins and combinations 
thereof. Methods and protocols for producing recombinant 
cells are known in the art. 
10 ylene alkyl ethers, polyoxyethylene castor oil derivatives, 
polyoxyethylene sorbitan fatty acid esters, polyethylene gly-
cols, polyoxyethylene stearates, colloidol silicon dioxide, 
phosphates, sodium dodecylsulfate, carboxymethylcellulose 
calcium, carboxymethylcellulose sodium, methylcellulose, 
C. Pharmaceutical Compositions 
15 hydroxyethylcellulose, hydroxypropylcellulose, hydrox-
ypropylmethycellulose phthalate, noncrystalline cellulose, 
magnesium aluminum silicate, triethanolamine, polyvinyl 
alcohol, polyvinylpyrrolidone, sugars and starches and mix-
tures thereof. 
Another embodiment provides pharmaceutical composi-
tions and dosage forms including the disclosed acellularized 
biomaterial. Pharmaceutical unit dosage forms of the com-
pounds of this disclosure are suitable for mucosa! (e.g., nasal, 20 
sublingual, vaginal, buccal, or rectal), parenteral (e.g., intra-
muscular, subcutaneous, intravenous, intra-arterial, or bolus 
injection), or topical administration to a patient. Examples of 
dosage forms include, but are not limited to: dispersions; 
ointments; cataplasms (poultices); pastes; powders; dress- 25 
ings; creams; plasters; solutions; patches; gels; and sterile 
solids suitable for parenteral administration to a patient. 
The composition, shape, and type of dosage forms of the 
compositions of the disclosure will typically vary depending 
on their use. These and other ways in which specific dosage 30 
forms encompassed by this disclosure will vary from one 
another will be readily apparent to those skilled in the art. See, 
e.g., Remington's Pharmaceutical Sciences, 18th ed., Mack 
Publishing, Easton, Pa. (1990). 
Pharmaceutical compositions and unit dosage forms of the 35 
disclosure typically also include one or more pharmaceuti-
cally acceptable excipients or diluents. Advantages provided 
by specific compounds of the disclosure, such as, but not 
limited to, increased solubility and/or enhanced flow, purity, 
or stability (e.g., hygroscopicity) characteristics can make 40 
them better suited for pharmaceutical formulation and/or 
administration to patients than the prior art. Suitable excipi-
ents are well known to those skilled in the art of pharmacy or 
pharmaceutics, and non-limiting examples of suitable excipi-
ents are provided herein. Whether a particular excipient is 45 
suitable for incorporation into a pharmaceutical composition 
or dosage form depends on a variety of factors well known in 
the art including, but not limited to, the way in which the 
dosage form will be administered to a patient. 
The disclosure further encompasses pharmaceutical com- 50 
positions and dosage forms that include one or more com-
pounds that reduce the rate by which the acellularized bio-
material will decompose. Such compounds, which are 
referred to herein as "stabilizers," include, but are not limited 
to, antioxidants such as ascorbic acid, pH buffers, or salt 55 
buffers. In addition, pharmaceutical compositions or dosage 
forms of the disclosure may contain one or more solubility 
modulators, such as sodium chloride, sodium sulfate, sodium 
or potassium phosphate or organic acids. A specific solubility 
modulator is tartaric acid. 
Like the amounts and types of excipients, the amounts or 
acellularized biomaterial in a dosage form may differ depend-
ing on factors such as, but not limited to, the route by which 
60 
it is to be administered to patients. However, typical dosage 
forms of the compounds of the disclosure are in an amount of 65 
from about 10 mg to about 1000 mg, preferably in an amount 
of from about 25 mg to about 750 mg, more preferably in an 
Depending on the specific tissue to be treated, additional 
components may be used prior to, in conjunction with, or 
subsequent to treatment with acellularized biomaterial of the 
disclosure. For example, protease inhibitors and other com-
pounds that prevent the degradation of the acellularized mate-
rial can be used. 
D. Combination Therapy 
The acellularized biomaterial derived from embryonic 
stem cells can be used in combination with a second thera-
peutic agent to facilitate healing and optionally, reduce or 
inhibit scarring. Suitable therapeutic agents include but are 
not limited to antibiotics, antioxidants, anti-viral agents, anti-
inflammatory agents, cytokines, and growth factors such as 
fibroblast growth factor, hepatocyte growth factor, platelet-
derived growth factor, vascular endothelial cell growth factor, 
and insulin-like growth factor. The amount of a second thera-
peutic generally depends on the tissue to be treated. Specific 
dosages can be readily determined by those of skill in the art. 
See Ansel, Howard C. et al. Pharmaceutical Dosage Forms 
and Drug Delivery Systems (6'h ed.) Williams and Wilkins, 
Malvern, Pa. (1995). Alternatively, the acellularized bioma-
terial can be used in combination with cell delivery, for 
example, the delivery of stem cells, pluripotent cells, somatic 
cells, or combinations thereof. 
III. Methods of Making Acellularized Biomaterials 
The disclosed biomaterial is obtained from cultured pluri-
potent cells such as stem cells undergoing differentiation or 
morphogenesis. A preferred method uses embryonic stem 
cells; however, it will be appreciated that any pluripotent cell 
can be used provided the cell can be induced to differentiate, 
for example into a specific cell or tissue or can develop at least 
one or more characteristics of a specific cell type or tissue 
type. The stem cells are induced to differentiate and typically 
form aggregates known as embryoid bodies. Conditions and 
growth factors for inducing stem cells to differentiate or pro-
duce specific cell types or tissues are known in the art. The 
embryoid bodies can be harvested at different time periods 
depending the type of cells or tissue to be treated. After the 
embryonic stem cells have differentiated, the biomaterial is 
harvested and acellularized. 
Acellularization is the process of removing cells from a 
tissue without disrupting the native structure and composition 
of its ECM. Examples of tissues that have been acellularized 
include porcine intestinal collagen layer, skin, bladder, 
human placenta, liver, and blood vessels, with applications 
varying from heart valves to nerve grafts. Some of the tissues 
are used to regenerate the same tissue, whereas others are 
used in different sites, such as SIS for tendon/ligament repair 
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or myocardial healing. Acellularization has been used to cre-
ate a number of different natural biomaterials since their 
ECM-based composition, largely conserved across species, is 
less likely to elicit an immune response. The wide range of 
these tissues that can be acellularized suggests the need for a 
variety of acellularization processes. Common protocols gen-
erally involve both physical and chemical means of disrupting 
cellular structure and removing their contents. Physical meth-
ods can involve freeze-thaw, pressure, and sonication tech-
niques. General mechanical agitation has also been used, 
though optimal cellular removal combines physical disrup-
tion with chemical extraction treatments. 
The variety of chemical procedures that have been used to 
acellularize different tissue samples can be categorized into 
alkaline or acid treatments, non-ionic or ionic detergents, and 
enzymatic treatments. Acid/alkaline treatments include ace-
regenerate properly and the normal wound healing process 
results in the formation of a permanent, fibrotic scar. Scar 
formation, instead of tissue regeneration, initiates a series of 
deleterious ventricular remodeling events that eventually lead 
to cardiac failure and mortality. Modulating and preventing 
scar tissue formation in the wounded heart could serve to 1) 
prevent adverse ventricular remodeling and 2) improve global 
cardiac function. Modulating the molecular composition of 
infarcted myocardial tissue to favor cardiomyogenic differ-
lO entiation provides a more conducive environment for cellular 
regeneration of the myocardial tissue by endogenous and 
optionally exogenous stem cell therapies. Thus, one embodi-
ment provides a method for treating a cardiac disease or 
15 disorder by administering acellularized biomaterial derived 
from embryonic stem cells to damaged or wounded cardiac 
tissue in an amount effective to heal or regenerate damaged 
cardiac tissue. 
tic acid, peracetic acid (PAA), and ammonium hydroxide, and 
are used to solubilize cellular cytoplasmic components and 
disrupt nucleic acids. PAA in particular has been found to be 
effective at removing cellular material while maintaining 
ECM components of thin tissues and serving as a disinfectant. 
Specifically, ECM proteins, GAGs, and growth factors are 
stably retained post-treatment. Ionic detergents have been 
used for solubilization of nuclear and cytoplasmic mem-
branes. Sodium dodecyl sulfate (SDS) in particular has been 
widely incorporated into acellularization protocols and was 
found to remove nuclear content, although it tended to sig-
nificantly disrupt ECM components. Non-ionic detergents, 
which disrupt lipid-lipid and lipid-protein interactions, are 
often used to lyse cellular membranes and offer a more gentle 30 
treatment. One of the most common detergents used is Triton 
X-100, although some studies have shown variable success in 
The wound can be external or internal. Typically, the acel-
20 lularized biomaterial is placed in contact with the wound so 
that the acellularized biomaterial physically interacts with 
cells of the wound or damaged tissue. If the wound is internal, 
the acellularized material can be administered surgically, or 
can be administered using a medical device adapted for deliv-
25 ering compounds internally, for example to the heart or other 
organ. 
B. Inhibition of Scarring 
The disclosed acellularized biomaterials can also be used 
to reduce scarring. It is believed that the embryonic environ-
ment prevents scar formation, permits tissue regeneration, 
and is distinctly different from that of an adult. Scar tissue 
its ability to remove cellular material. Similarly, conflicting 
reports exist on the maintenance of ECM components after 
Triton X-100 treatment, where in some cases, use of the 35 
reagent removed all GAG content, while in other cases an 
insignificant difference in GAG and collagen components 
was observed. Finally, enzymatic treatments such as trypsin 
and DNase have been used to either cleave peptide bonds or 
digest nucleotides. Conflicting reports on the varying sue- 40 
cesses of similar acellularization treatments on different tis-
sues lends support to the notion that different reagents must 
formation is a common adverse response exhibited by most 
adult mammalian species as a result of acute injury or chronic 
diseases resulting in abnormal tissue structure. Typically, 
pluripotent embryonic stem cells are used as a robust cell 
source for the treatment of various degenerative diseases that 
cause irreplaceable endogenous cell loss. It has been discov-
ered that the disclosed acellularized biomaterials derived 
from embryonic stem cells can be used to mimic the embry-
onic microenvironment in adult tissues and reduce scarring. 
During the early stages of development, mammalian 
fetuses possess the ability to heal injuries in a scar-free man-
ner, whereas a permanent transition occurs later during ges-
be optimized for each tissue by controlling the concentrations 
and durations of treatments significant effects on the acellu-
larized product. 45 tation whereby tissue injury results in scar formation rather 
than tissue regeneration. The curious ability of fetuses to heal 
wounds has long baffled scientists, but has also provided 
model systems to identify and characterize the role of various 
A preferred method for acellularizing biomaterial pro-
duced by embryonic stem cells includes treating the bioma-
terial with a combination of a detergent and DNAase as 
described in Example 1. An exemplary method provides 
treating embryoid bodies with 0.1 to 1 % (w/v) of detergent, 50 
for example a nonionic detergent, and 1 mg/ml DNase for 
about 30 minutes. The biomaterial to be acellularized can be 
allowed to differentiate in vitro for any length of time, for 
example, about 1 hr to about 12 hrs, or 1, 2, 3, 4, 5, 6, 7, 8, 9, 
molecules that either stimulate or antagonize proper wound 
healing rather than scar tissue formation. Similar regenera-
tion capabilities have also been described in other systems, 
specifically newts and the MRL strain of mice. Scarless 
wound healing is desirable because the excessive ECM reor-
ganization associated with scarring results in compromised 
10, 11, 12, 13, 14, or more days. 
IV. Methods of Use 
A. Wound Healing 
The disclosed acellularized biomaterial is useful for pro-
moting or inducing wound healing in adult tissue, in particu-
lar cardiac or neural wound healing. The acellularized bio-
material can be delivered to a wound or damaged tissue, for 
example tissue that has lost the capacity to regenerate on its 
own. 
Mammalian adult myocardium lacks inherent regenerative 
capacity since mature cardiomyocytes exhibit a limited abil-
ity to proliferate in response to injury. Thus, following an 
incidence of ischemia, infarcted myocardial tissue fails to 
55 tissue function and decreased mechanical strength of the 
injured area. Additionally, hallmarks of fetal repair involve 
hair follicle and sebaceous gland regeneration. The skin 
wound healing model has long been recognized as the most 
relevant system for studying scarless regeneration in fetuses 
60 and adults. Accordingly, a number of different models have 
been created to examine the mechanisms of wound repair of 
the skin, such as excisional, incisional and bum wounds. Each 
of these models have distinct advantages and disadvantages 
compared to the others, but the excisional wound model pro-
65 vides an easily reproducible wound that can be tracked visu-
ally during the time course of healing and is amenable to a 
number of quantitative measures of tissue repair, such as 
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wound closure rate, reepithelializationrate and thickness, and 
the density of cell invasion by macrophages and blood ves-
sels. 
One embodiment provides acellularized biomaterial 
derived from differentiating embryonic stem cells that is 
capable of reducing scar formation in a wound or damaged 
tissue. It is believed that the acellularized biomaterial mimics 
12 
ing process, for example by regenerating the tissue, produc-
ing growth factors or cytokines, dividing, or a combination 
thereof. 
in adult tissues, at least in part, the embryonic microenviron-
ment. The acellularized biomaterial can be placed in contact 
with a wound or damaged tissue. The acellularized biomate-
rial can then physically interact with the wound or damaged 
tissue to stimulate existing cells to heal with little or no scar 
formation relative to a control. Alternatively, paracrine fac-
tors associated with the acellularized biomaterial can stimu- 15 
Still another embodiment provides a method for treating 
cardiac disease by contacting diseased or damaged cardiac 
tissue with acellularized biomaterial derived from embryonic 
stem cells undergoing cardiomyogenic differentiation. The 
acellularized biological material can be administered in an 
amount effective to promote or induce healing relative to a 
10 
control. 
late the cells in the wound or tissue to heal with little or no scar 
formation relative to a control. 
C. Scaffolding 
Yet another embodiment provides a method for treating 
neural disease by contacting diseased or damaged neural 
tissue with acellularized biomaterial derived from embryonic 
stem cells undergoing neural differentiation. 
Another embodiment provides a method for treating 
muscle disease by contacting diseased or damaged muscle 
tissue with acellularized biomaterial derived from embryonic 
stem cells undergoing myogenic differentiation. 
Another embodiment provides a method for treating skin 
disease by contacting diseased or damaged skin with acellu-
larized biomaterial derived from embryonic stem cells under-
going epithelial differentiation. 
Another embodiment provides a substrate or scaffold con-
taining the disclosed acellularized biomaterial. The substrate 20 
or scaffold can be used to produce specific three dimensional 
constructs containing predetermined cells or tissue types. For 
example, a substrate or scaffold containing acellularized bio-
material specific for inducing the production of arterial tissue 
can be used to produce a three dimensional arterial construct. 
The construct can be produced by seeding the substrate or 
scaffold with totipotent or pluripotent cells which interact 
with the acellularized biomaterial and differentiate into arte-
rial tissue. The substrate of scaffold directs the shape or form 
Another embodiment provides a method of inducing car-
25 tilage formation by administering acellularized biomaterial 
derived from embryonic stem cells undergoing differentia-
tion to generate cartilage producing cells. 
of the construct, for example, the construct can be tubular or 
planar. 
Exemplary scaffolds or substrates are biodegradable or 
formed of biodegradable polymers. In other embodiments, 
the scaffolds or substrates are made of synthetic polymers 
including, but not limited to polyesters, polyurethanes, poly-
ethers, polyamides, polyimides, or combinations thereof. 
D. Methods of Treatment 
The disclosed acellularized biomaterial can be used alone 
or in combination with autologous or heterologous cells 
including, but not limited to adult stem cells, embryonic stem 
cells, pluripotent cells, or somatic cells for promoting wound 
healing, for example by contacting a wound surface with 
acellularized biomaterial derived from one or more embry-
onic stem cells in an amount effective to promote or induce 
healing relative to a control. The cells can be added to the 
acellularized biomaterial before administration or after 
administration. One of skill in the art can readily ascertain "an 
amount effective to promote or induce healing relative to a 
control" using conventional techniques. 
One embodiment provides a method for reducing scarring 
The disclosed acellularized biomaterial, alone or in com-
bination with autologous or heterologous cells, for example 
30 pluripotent cells can be used to treat a variety of degenerative 
diseases. Representative disease that can be treated include, 
but are not limited to Alzheimer's disease, amyotrophic lat-
eral sclerosis (ALS), atherosclerosis, cancer, diabetes, heart 
disease, inflanmiatory bowel disease (IBD), Parkinson's dis-
35 ease, prostatitis, osteoarthritis, and osteoporosis. 
V. Devices 
One embodiment provides a device for example a wound 
dressing. The wound dressing includes a backing having acel-
lularized biomaterial derived from differentiating embryonic 
40 stem cells thereon. The wound dressing is applied to a wound 
so that the acellularized biomaterial contacts the wound and 
physically interacts with cells of the wound. The backing can 
be a fabric, felt, mesh, or polymer. The wound dressing 
optionally includes a moisture regulation layer, an absorbent 
45 layer, and adhesive flanking the acellularized biomaterial. 
The absorbent layer can be positioned between the backing 
and the acellularized biomaterial. 
Another embodiment provides a stent having acellularized 
biomaterial derived from pluripotent cells, for example dif-
50 ferentiating embryonic stem cells. The acellularized bioma-
terial can be on an external surface of the stent or an internal 
surface of the stent. Typically, the exterior surface of the stent 
is at least partially, preferably completely coated with the 
by contacting a wound with acellularized biomaterial derived 
from one or more differentiating embryonic stem cells in an 
amount effective to reduce scarring relative to a control. The 
acellularized biomaterial can be administered repeatedly as 55 
needed. In certain embodiments, the acellularized biomate-
rial is harvested from pluripotent cells induced to differentiate 
into the cells or tissue similar to the tissue to be treated. Thus, 
acellularized biomaterial, for example, in an amount effective 
to reduce arterial scarring. Stents are known in the art, and the 
disclosed acellularized biomaterial is not limited to use with 
any one stent or class of stent. 
It will be appreciated that the disclosed acellularized bio-
material can be used in combination with a variety of medical 
devices that are implanted into a patient, for example a human 
patient. The medical device is typically coated with acellu-
if the wound is in cardiac tissue, the acellularized biomaterial 
is harvested from pluripotent cells differentiating into cardiac 60 
cells or cardiac tissue. 
Another embodiment provides a method for promoting 
tissue growth by contacting a tissue with acellularized bio-
material derived from one or more differentiating embryonic 
stem cells in an amount effective to promote endogenous 65 
tissue growth. In this embodiment, the acellularized bioma-
terial induces the cells of the tissue to participate in the heal-
larized biomaterial in amounts effective to reduce scarring, to 
facilitate tissue integration, or both relative to a control. 
Exemplary implanted medical devices include but are not 
limited to pace makers, orthopedic implants, drug delivery 
devices, catheters, biosensors, dental implants, prosthetics, 
screws, braces, and pins. 
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Another embodiment provides a kit. The kit includes acel-
lularized biomaterial derived from differentiating pluripotent 
cells, for example embryonic stem cells. The acellularized 
biomaterial can be packaged individually and can include 
buffers, reagents, written directions, and an applicator for 
administering the device. 
EXAMPLES 
14 
Protein Quantification 
Untreated EBs and acellular samples were solubilized 
using 6M guanidine hydrochloride (GuHCl). Total protein 
content was assessed using the bicinchoninic acid (BCA) 
assay kit (Pierce). Samples and standards created from known 
concentrations of bovine serum albumin (20-2000 µg/mL) 
were incubated in the BCA solution for 30 minutes at 37° C., 
and absorbance readings were taken at 562 nm on a Spectra-
Max M2e plate reader. Unknowns were fitted to the albumin 
Methods and Materials 
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standard curve to determine protein concentration. 
DNA Quantification DNA content of treated and untreated 
samples was quantified using the Quant-iT™ PicoGreen® 
dsDNAAssay kit (Molecular Probes). Samples were solubi-
lized using 6M GuHCl and added to 20xTE buffer (200 mM 
Tris-HCl, 20 mM EDTA, pH=7.5) and PicoGreen dye solu-
Mouse embryonic stem cells (D3) were cultured on gela-
tin-coated dishes with Dulbecco's modified eagle medium, 
supplemented with 15% fetal bovine serum, 2 mM 
L-glutamine, non-essential amino acids, antibiotic/antimy-
cotics, and 0.1 mM ~-mercaptoethanol. To maintain the cells 
15 tions. Fluorescent measurements of unknowns and calf thy-
mus DNA standards were taken using a SpectraMax M2e 
plate reader (ex: 485 nm, em: 528 nm). Unknowns were fitted 
to standard curves to determine DNA content. in their undifferentiated state, 10
3 U/ml leukemia inhibitory 
factor (LIF) (ESGRO) was added to the culture. Cells were 
passaged every two to three days when they reached - 70% 20 
confluence. For this study, cells were used at passages 20-30. 
To initiate embryoid body culture, ESCs were trypsinized and 
removed from the gelatin-coated dishes. Four million cells 
were transferred to non-tissue culture treated Petri dishes 
(Day 0) and placed on orbital rotary shakers at 40 rpm. EBs 25 
were fed every other day with differentiation media not con-
taining LIF. 
Acellularization 
Embryoid bodies were harvested at days 4, 7, and/or 10 of 
differentiation. Equal amounts of starting material (EBs) 30 
were distributed across microcentrifuge tubes. For mass 
retention analyses, each tube was weighed before addition of 
the sample. Control EBs were either rinsed in phosphate 
buffered saline (PBS) and stored in 4° C. for subsequent 
solubilization or kept in serum-free media at 37° C. for cell 35 
viability measurements. Treatment groups were centrifuged 
Mass Retention 
Untreated and acellularized EBs were rinsed twice in 
dH20 and stored overnight at -80° C. Samples were then 
freeze-dried for 24 hours using a Labconco lyophilizer and 
weighed. Mass retention was recorded as the difference 
between averaged untreated EBs and acellular material. All 
samples were created from the same amount of starting mate-
rial. 
Histology and Immunohistochemistry (IHC) 
EBs were harvested by allowing the cell clusters to settle to 
the bottom of a tube. EBs or acellular products were incu-
bated in either methyl carnoy or formalin fixatives for 30 
minutes and embedded in Histogel®. Samples were then 
processed for histological sectioning through a series of 
xylene and alcohol rinses and paraffin embedding. Each 
group was sectioned into 5 µm slices and de-paraffinized. 
Some samples were stained with hematoxylin and eosin 
(H&E) using an Lei ca Auto stainer XL. Sections undergoing 
IHC were washed in xylene and 100% ethanol (EtOH) after 
de-paraffinization. Endogenous peroxidase activity was 
quenched using 0. 7 5% hydrogen peroxide in 100% methanol, 
after which the samples were hydrated in graded ethanol 
series (100% EtOH-35% EtOH) and rinsed in phosphate-
buffered saline (PBS, pH 7 .3 ). Samples were incubated in 1 % 
bovine serum albumin for 30 minutes before addition of the 
hyaluronan binding protein (HABR-B) and an overnight 
incubation at 4 ° C. The Vector Elite ABC kit was then used for 
at 18,000 ref for two minutes before addition of the reagent 
being tested. Samples were rotated in a LabQuake Rotisserie 
for the desired period of time, spun down at 18, 000 ref for two 
minutes, rinsed twice with PBS, and, if applicable, rotated in 40 
a second reagent for a given amount of time. At the end of the 
treatment, samples were centrifuged for two minutes at 
18,000 ref, and rinsed twice in PBS. Reagents tested were 
combinations of Triton X-100 (VWR) and Dnase (-2,000 
Kunitz units/mg, Worthington Biochemical Corp.). 45 color staining development prior to counterstaining in Gills 
#3 hematoxylin. Coverslips were mounted on each sample 
using aqueous mounting medium with anti-fading agents 
(Biomeda Corp.) and imaged using a Nikon 80i Upright 
Microscope and SPOT imaging software. 
Scanning Electron Microscopy 
Untreated EBs and acellular samples were fixed in gluter-
aldehye (2.5% in 0.2M cacodylate buffer) and post-fixed in 
1 % Os04 (Electron Microscopy Sciences). Samples were 
rinsed three times in 0.2M cacodylate buffer and transferred 50 
into acetone immediately prior to drying in a critical point 
dryer (Quorum Technologies). Each sample was gold sputter 
coated for 90 seconds in a sputter coater and viewed using the 
Hitachi S800 Scanning Electron Microscope. 
Immunofluorescence (IF) 
Samples fixed in 10% formalin were prepared for staining 
as stated above. After deparaffinization, histological sections 
were permeabilized and blocked for 45 minutes using 2% 
goat serum (GS) and 0.05% Triton X-100. Samples were 
incubated with collagen IV, fibronectin, or laminin-1 primary 
Cell Viability 55 antibodies (polyclonal rabbit) overnight at 4° C. (1:80 dilu-
tion), rinsed with PBS, and then incubated with FITC-conju-
gated goat anti-rabbit secondary antibody (1: 100 dilution) 
before counterstaining using Hoechst. Finally, coverslips 
Immediately after collection and treatment, untreated EBs 
and acellular samples were incubated in alamarB!ue solution 
(10% alamarB!ue in serum-free media) for three hours (Bio-
source ). Fluorescent measurements were taken (ex: 545 nm, 
em: 590 nm) using a SpectraMax M2e plate reader; readings 60 
were normalized to values obtained for untreated EBs to 
obtain relative values of percent viability. Additionally, live/ 
dead staining was performed to corroborate the quantitative 
alamarB!ue data. Untreated and treated EBs were transferred 
into wells of a six-well dish and incubated. The samples were 65 
then imaged using a TE inverted fluorescent microscope to 
capture both green and red fluorescence. 
were mounted using an aqueous mounting medium with anti-
fading agents (Biomeda Corp.) and imaged using a Nikon 80i 
Fluorescent Upright Microscope. 
Example 1 
Acellularization of Embryoid Bodies 
Acellularization experiments were performed for varia-
tions in concentration and treatment time for Triton X-100 
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and DNase. Triton and DNase were evaluated for concentra-
tion optimizations using cell viability as a protocol efficiency 
indicator (FIGS. lA and B). Viability was significantly inhib-
ited in all cases, with no significant differences between each 
group. 
Triton and DNase concentrations as well as treatment times 
were also evaluated via total protein content (FIGS. 2A-D). 
While protein content was retained in each experimental 
group, there were no significant differences within the Triton 
concentrations, the DNase concentrations, or the DNase 
10 
treatment times. Within the Triton treatment times analyzed, 
a 30-minute period retained significantly more protein than 
both the 60- and 90-minute durations. 
Finally, the combination of reagents was analyzed by 
evaluating cell viability, total protein content, and cell density 
when using Triton only, DNase only, and a combination of 15 
Triton and DNase (FIG. 3A-C). The Hoechst staining showed 
that nuclei were distinct in the untreated EBs, while all treat-
ment groups showed either diffuse or absent nuclear staining. 
Images of Triton alone and DNase alone indicated that some 
nuclear material was present, although not as distinct as 20 
untreated samples, while little DNA signal was left when a 
combination of Triton and DNase was used. Quantification of 
cell nuclei further supported the use of Triton and DNase 
together for efficient cell removal. Additionally, cell viability 
data indicated the some viability remained in the Triton alone 25 
and DNase alone samples, while it was reduced below the 
assay detection limits forthe combination of reagents. Protein 
content was also found to be retained in all samples. 
16 
on total protein content, DNA content, and mass retention 
over the course of differentiation was performed on the final 
protocol (FIG. SA-C). Protein content was maintained at days 
4, 7, and 10. Additionally, DNA content was significantly 
reduced at each time point, with almost no remaining DNA 
left at day 4 and slightly more at days 7 and 10. Finally, mass 
was retained at days 7 and 10, suggesting that some material 
was left after the extraction process. 
Example 4 
Cell Viability and Component Retention 
Cell viability over the course of differentiation was ana-
lyzed using both quantitative and visual assays. The Live/ 
Dead assay showed all live and no dead cells over the course 
of differentiation of untreated EBs. Acellular material 
showed mostly dead cells at days 4 and 10, with some live at 
day 7. This visual information was corroborated with the 
quantitative alamarB!ue data, which showed viability below 
the levels of the assay's detection limit at days 4 and 10, and 
-25% viability at day 7 (FIG. 6). 
Initial studies to analyze which extracellular matrix com-
ponents remained after the extraction process were per-
formed using immunostaining. Collagen IV, laminin-1, and 
hyaluronan content was visualized in untreated EBs and acel-
lular material. All three components were spatially spread 
around the untreated EBs. Hyaluronan seemed to localize at 
areas of lower cell density. Importantly, significant amounts 
of the individual proteins or glycosaminoglycans were main-
tained through acellularization and were found to be present 
throughout the final product. 
Example 5 
Cardiomyogenic Differentiation of ES Cells 
Mouse ES cells are typically induced to differentiate via 
embryoid body (EB) formation by either the hanging drop 
The optimized protocol using Triton and DNase together 
was further investigated through variations in DNase treat-
30 
ment times and concentrations, neither of which made a sig-
nificant difference with viability, total protein content, or 
DNA content (FIG. 4A-C). DN ase was mixed with 1 % Triton, 
but this change in procedure made no significant difference in 
improving the existing protocol, in which Triton and DNase 
are used sequentially. Peracetic acid was investigated as an 35 
additional or alternative treatment, but was not found to sig-
nificantly improve the efficiency of the Triton/DNase proto-
col. Additionally, EBs were cultured using ascorbic acid as an 
attempt to enhance quantity and protein content of the final 
acellular product (data not shown). 40 technique or static suspension culture, although both methods 
have inherent limitations. While EBs produced by hanging 
drops are more uniform in size, shape and subsequent differ-
entiation behavior, the need to keep individual drops physi-
Example 2 
Histology 
45 
H&E-stained sections of untreated and treated EBs showed 
cally separated prevents efficient production of a large num-
ber ofEBs. Static suspension cultures, on the other hand, can 
be easily initiated from a cell suspension, but the resulting 
the agglomeration of individual EBs after acellularization. 
While the EBs appeared to take on a more differentiated 
morphology, the acellular material showed little change over 
the course of differentiation. Individual cells were clearly 
present in the untreated EBs, while distinct nuclei were no 
longer observed in the acellular material. 
Scanning electron micrographs at various magnifications 
display the surface detail of untreated EBs, as well as the 
surface and cross-section of acellular EBs. Images of the 
cross-section showed the porous nature of the product's inte-
rior, while comparisons between the acellular and untreated 
surfaces indicated that the acellularization procedure 
removed or destroyed individual cells and created one rela-
tively uniform and flat material. 
Example 3 
Acellularization Protocol Analysis: Protein, DNA, 
and Mass Quantification 
Once it was established that a combination of Triton and 
DNase was most efficient in acellularizing the EBs, analysis 
EBs vary widely in size, shape and differentiation. In addi-
tion, during static suspension, EBs often prematurely attach 
to the surface of the Petri dish, reducing the overall yield of 
50 differentiated cells, unless low-adhesion surface coatings are 
employed. It was recently discovered that by simply placing 
suspension EB cultures in untreated bacteriological dishes on 
a rotary plate during EB formation, the homogeneity of EB 
size and shape can be significantly improved as well as the 
55 overall yield ofEBs and the reproducibility of differentiation. 
Mouse ES cells (D3 line) were cultured under feeder-free 
growth conditions in the presence of LIF (103 U/ml). To 
initiate differentiation, LIF was removed from the culture 
media and EBs were placed in hanging drops on the lids of 
60 Petri dishes (600 cells/15 µl drop) or in suspension culture 
(4xl05 cells/ml; 10 ml/100 mm dish). Rotary suspensions 
were achieved by placing suspension dishes on a rotary plate 
(Barnstead Thermolyne) within a humidified C02 incubator. 
After 4 days of differentiation, phase contrast images of EBs 
65 formed by the different methods were obtained and the cross-
sectional area and shape factor (defined as the minor axis 
divided by the major axis) of individual EBs were measured 
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with ImageJ software. Molphometric analysis indicated that 
the rotary cultures were similar in size and shape to the 
hanging drop EBs, whereas the static cultures were notice-
ably irregular. There was also a greater number of EBs pro-
duced in rotary cultures than in static cultures inoculated with 
an equivalent number of cells (FIG. 7). 
18 
cantly decreased by DNase treatment alone and completely 
abrogated by Triton X-100 treatment, indicating successful 
acellularization of the EBs. Similar results have also been 
obtained from acellularized EBs after 7 days of differentia-
tion, indicating that the timing of cell extraction can be selec-
tively controlled. 
In summary, the aforementioned studies have established 
that acellularization of EBs by solvent extraction methods 
yields a novel biomaterial derived from ES cells during the 
10 course of in vitro differentiation. 
Cardiogenesis of the EBs formed by the different methods 
was examined by counting the percentage of beating EBs 
upon plating and assessing the gene expression profile of the 
cells during the time course of differentiation. One day after 
plating (day 8 of differentiation), the percentage of EBs that 
contained at least one beating foci was about 60% for both 
hanging drop and rotary cultures, whereas fewer than 10% of 
the static EBs exhibited contractile areas (FIG. 8). While the 
percentage of contractile hanging drop EBs increased slightly 15 
over time (to -80%), the number of beating rotary EBs 
remained relatively constant (-50% ), but the contractile areas 
increased in size and contracted more vigorously. In addition, 
the number of beating foci within EBs from rotary cultures 
appeared to increase over the time course examined, but this 20 
was not quantifiable due to difficulties in discriminating 
between distinct and merged foci within individual EB out-
growths. 
Semi-quantitative real-time PCR analysis indicated a more 
pronounced decrease in Nanog expression (a pluripotent stem 25 
cell marker) in hanging drop and rotary EBs than in static 
suspensions (FIG. 9A), suggesting more efficient induction 
of differentiation. Rotary EBs exhibited a significant increase 
in mesoderm formation, based on Brachyury-T expression, 
after 4 days compared to hanging drop and static suspension 30 
EBs, although the weaker levels of Brachyury T in hanging 
drops at 4 days could be related to the rapidly transient nature 
of its expression during differentiation (FIG. 9B). Cardi-
omyocyte gene expression, based on MLC-2v expression, 
was also significantly greater in both hanging drop and rotary 35 
EBs at day 7 of differentiation than in static suspension EBs 
(FIG. 9C). Thus, gene expression results correlated with the 
observed differentiation and contractile activity of the plated 
EBs, suggesting that the rotary culture method is an effective 
means of promoting cardiomyogenic differentiation from ES 40 
cells with an overall greater yield of EBs than either hanging 
drop or suspension methods. 
Example 7 
Cardiac Grafting of Acellularized Materials 
Acellularized EB material was grafted onto the epicardial 
surface of infarcted hearts of male CD Frats immediately after 
being subjected to a left coronary artery ligation. Acellular 
materials (-2x2 mm) were affixed to the hearts with one drop 
(<100 µl) of fibrin glue. Hearts were retrieved 1or13 days 
later, fixed and stained with hematoxylin and eosin. After 1 
day, the material was retained on the surface of the heart 
adjacent to the developing infarcted tissue and was largely 
free of any cell nuclei. By 13 days, the acellular material was 
no longer readily discernible and significant differences were 
apparent in the healing response, wall thickness and chamber 
size for infarcted hearts with the acellular material, compared 
to untreated controls. These results show that acellular ECM 
from ES cells can be grafted onto infarcted rat hearts and alter 
the course of normal ventricular remodeling after myocardial 
infarction. 
Unless defined otherwise, all technical and scientific terms 
used herein have the same meanings as commonly under-
stood by one of skill in the art to which the disclosed invention 
belongs. Publications cited herein and the materials for which 
they are cited are specifically incorporated by reference 
where permissible. 
Those skilled in the art will recognize, or be able to ascer-
tain using no more than routine experimentation, many 
equivalents to the specific embodiments of the invention 
described herein. Such equivalents are intended to be encom-
passed by the following claims. 
We claim: 
Example 6 1. A composition comprising acellularized embryoid-
45 body-biomaterial comprising a combination of paracrine fac-
Acellularized Biomaterial for Cardiac Tissue Repair tors produced by one or more differentiating embryoid bodies 
in an amount effective to promote or induce wound healing 
Mouse ES cells were cultured and differentiated via EB relative to a control. 
formation as described above. After 4 days of differentiation, 
the resulting EBs were harvested and subjected to detergent 50 
and/or enzymatic treatments in an attempt to extract cellular 
material and retain the residual insoluble ECM. EB samples 
were treated with TritonX-100 (0.1%or1 % w/v) or DNase (1 
mg/ml) solutions for 30 minutes. The resulting material was 
analyzed histologically by Hoechst staining. Mass retention 55 
was calculated from pre- and post-treatment values and cell 
viability was measured with the Alamar Blue assay (Bio-
source ). Acellularization with Triton X-100 induced the indi-
vidual EBs to aggregate within minutes, forming a viscous 
mass of contiguous material readily retrievable by centrifu- 60 
gation. Histology indicated TritonX treatment (0.1%) alone 
disrupted the normal distinct, round cell nuclei morphology 
to yield a fibroporous acellular material. Mass calculations of 
the starting and final material indicated that a majority of the 
mass was retained following acellularization (-70-80% ), and 65 
the percentage of mass retained decreased with increasing 
concentration of Triton X-100. Cell viability was signifi-
2. The composition of claim 1, wherein the one or more 
differentiating embryoid bodies undergo cardiac differentia-
tion, neural differentiation, myogenic differentiation, epider-
mal differentiation, or a combination thereof. 
3. The composition of claim 1, wherein the one or more 
embryoid bodies comprises a heterologous nucleic acid. 
4. A pharmaceutical composition comprising acellularized 
embryoid-body-biomaterial produced by a process compris-
ing acellularizing one or more in vitro differentiating embry-
oid bodies wherein the acellularized embryoid-body-bioma-
terial comprises a combination of paracrine factors produced 
by differentiating embryoid bodies in an amount effective to 
promote or induce wound healing. 
5. The pharmaceutical composition of claim 4, further 
comprising an excipient. 
6. A composition comprising acellularized embryoid-
body-biomaterial produced by a process comprising acellu-
larizing in vitro differentiating embryoid bodies, wherein the 
acellularized embryoid-body-biomaterial comprises an 
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effective amount of a combination of paracrine factors pro-
duced by the differentiating embryoid bodies to alter the 
microenvironment of a wound or damaged tissue to induce or 
facilitate regenerative tissue repair in vivo. 
7. A medical device comprising acellularized biomaterial 
according to claim 1 or 6. 
8. The medical device of claim 7, wherein the device is 
selected from the group consisting of a wound dressing, stent, 
orthotic, suture, implant, catheter, rod, pin, delivery vehicle, 
and brace. 10 
9. A kit comprising acellularized biomaterial according to 
claim 1, 4, or 6. 
10. The kit of claim 9, further comprising one or more 
pluripotent cells. 
11. The kit of claim 9, wherein the acellularized biomate- 15 
rial is tissue specific. 
12. The composition of claim 1, wherein the acellularized 
embryoid-body-biomaterial is non-human. 
* * * * * 
